BioSpace News Archive

Axon (Nasdaq: AAXN), the global leader in connected public safety technologies, today announced Axon’s new empathy development training for suicide prevention, based in virtual reality.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 3:00 p.m. Eastern Time in New York, NY.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from its prostate cancer and solid tumor portfolios will be featured at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain.

Washington University School of Medicine in St. Louis will use the uMR 570, enhanced with artificial intelligence, to advance the field of cardiovascular MR

Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), an agriculture technology and rural e-commerce company, today announced that the Company has entered into a collaboration agreement with Inova Genética Ltda (INOVA), a member of the Wehrmann Group, from Cristalina-GO, Brazil.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has completed its site initiation visit for the first site to be included in its upcoming keloid scar proof-of-concept trial.

Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the closing of the Company’s previously announced initial public offering of 5,500,000 shares of common stock at a public offering price of $15.00 per share,

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans for the transition of Executive Vice President and Chief Financial Officer Paul Clancy later this year.

Accuray Incorporated announces that The Lancet Oncology, a high impact and leading global peer-reviewed oncology journal, has published patient- and clinician-reported outcomes data from the PACE — Prostate Advances in Comparative Evidence — trial in its most recent issue.

Health Canada recently informed Canadians that it is assessing the issue of an impurity called N-nitrosodimethylamine detected in some ranitidine drugs.